Factor XI antibodies and methods of use

US11168147B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Maximilian Aigner · Redmond, US
• Alexander Koch · Arlington, US
• Markus Waldhuber · Munich, DE

Key dates

• Filing date: Dec 21, 2017
• Grant date: Nov 9, 2021
• Expiry date: Jul 9, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.